Clinical Trials Logo

Stage IV Ovarian Germ Cell Tumor clinical trials

View clinical trials related to Stage IV Ovarian Germ Cell Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT00436254 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Start date: October 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with sargramostim may be an effective treatment for breast cancer and ovarian cancer. PURPOSE: This phase I trial is studying the side effects and identifying the best dose of vaccine therapy when given together with sargramostim in treating patients with stage III-IV breast cancer or ovarian cancer.